Clinicians discuss the particular benefits of rapid-acting agents for major depressive disorder (MDD), highlighting the gap glutamate-modulating agents fill in targeted therapies.
San Diego, California (Newsfile Corp. - December 14, 2021) - Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company developing advanced drug delivery technologies for use with psychedelic
/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.